Earlier this month, the Substance Abuse and Mental Health Services Administration (SAMHSA) released its annual National Survey on Drug Use and Health (NSDUH), which examined substance use and mental health data from 2021. Although the survey has been administered since 1971, SAMHSA called this year’s “the most comprehensive report on substance use and mental health indicators” that the organization has released to date.
Over seven years ago, I founded Holmusk with the vision that advances in technology and data science could be harnessed to improve health care. Over the company’s lifespan, the vision has crystallized, and we decided to focus first on an area of dire need—behavioral health. We have made great advancements in this space, many of which would not have been realized without the creation and nurturing of fruitful and supportive partnerships.
What if we could better understand the effects of treatments on specific types of individuals, thereby allowing us to personalize drug treatments?
This blog post is a continuation of our Data Differentiators series, in which we’re sharing how the NeuroBlu Database stands out from other EHR-derived real-world data sources. For previous installments of the series, see here and here.
This blog post is a continuation of our Data Differentiators series, in which we’re sharing how the NeuroBlu Database stands out from other EHR-derived real-world data sources. For previous installments of the series, see here.
Our mission is to build the world’s richest real-world evidence platform for behavioral health to transform clinical research and care delivery. Our NeuroBlu Database delivers value to our customers by providing meaningful clinical information that helps to produce evidence that could not be easily generated otherwise.
Today marks World Mental Health Day, a day of recognition organized and sponsored by the World Health Organization. All month, we will also honor ADHD Awareness Month by looking back at some of the most important ADHD research we have done this year.
This Saturday marks the annually recognized World Suicide Prevention Day, organized by the International Association for Suicide Prevention and endorsed by the World Health Organization. This day is critical to recognize, as we know that an estimated 703,000 people globally die by suicide each year. In keeping with this year’s theme, “Creating hope through action,” I wanted to reflect for a moment on the work we at Holmusk undertake with our partner NHS Trusts year-round to address this urgent matter.
This year at the American Society of Clinical Psychopharmacology’s annual conference, I had the privilege to organize and chair a panel discussion on challenges and opportunities in leveraging real-world evidence to inform the development of new treatments in behavioral health.
On Clinical Trials Day, we recognize an important part of the healthcare infrastructure: the studies that rigorously evaluate new treatments to determine which will be effective and safe for improving patient health. Through the conventional process of assessment, the treatments that succeed will go on to regulatory approval and will be marketed to patients and their providers.
